Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.

E Muñoz-AceitunoB Butrón-Bris María C Ovejero-Benito Antonio Sahuquillo-TorralbaO Baniandrés RodríguezE Herrera-AcostaRaquel Rivera-DíazM FerranJ L Sánchez-CarazoJosep Riera-MonroigJ Pujol-MontcusíD VidalPablo de la Cueva-DobaoM García-BustinduyRicardo Ruiz VillaverdeF BallescàMar Llamas VelascoM NavaresI Palomar-MorenoI Sánchez-GarcíaJ García-MartínezJ NovalbosP ZubiaurF Abad-SantosEsteban Daudén Hortensia de la Fuente

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non-response to this drug in patients with plaque psoriasis.

Keyphrases

end stage renal disease
clinical practice
ankylosing spondylitis
ejection fraction
newly diagnosed
chronic kidney disease
coronary artery disease
prognostic factors
peritoneal dialysis
risk assessment
climate change
human health
adverse drug
disease activity